Alligator Bioscience AB, of Lund, Sweden, said it will present preclinical safety data for drug candidate ATOR-1017 at the CRI-CIMT-EATI-AACR International Cancer lmmunotherapy conference in New York. Monoclonal antibody ATOR-1017 is in development for the treatment of metastasizing cancer.